» Articles » PMID: 26574188

External Evaluation of Published Population Pharmacokinetic Models of Tacrolimus in Adult Renal Transplant Recipients

Overview
Specialty Pharmacology
Date 2015 Nov 18
PMID 26574188
Citations 44
Authors
Affiliations
Soon will be listed here.
Abstract

Aim: Several tacrolimus population pharmacokinetic models in adult renal transplant recipients have been established to facilitate dose individualization. However, their applicability when extrapolated to other clinical centres is not clear. This study aimed to (1) evaluate model external predictability and (2) analyze potential influencing factors.

Methods: Published models were screened from the literature and were evaluated using an external dataset with 52 patients (609 trough samples) collected by postoperative day 90 via methods that included (1) prediction-based prediction error (PE%), (2) simulation-based prediction- and variability-corrected visual predictive check (pvcVPC) and normalized prediction distribution error (NPDE) tests and (3) Bayesian forecasting to assess the influence of prior observations on model predictability. The factors influencing model predictability, particularly the impact of structural models, were evaluated.

Results: Sixteen published models were evaluated. In prediction-based diagnostics, the PE% within ±30% was less than 50% in all models, indicating unsatisfactory predictability. In simulation-based diagnostics, both the pvcVPC and the NPDE indicated model misspecification. Bayesian forecasting improved model predictability significantly with prior 2-3 observations. The various factors influencing model extrapolation included bioassays, the covariates involved (CYP3A5*3 polymorphism, postoperative time and haematocrit) and whether non-linear kinetics were used.

Conclusions: The published models were unsatisfactory in prediction- and simulation-based diagnostics, thus inappropriate for direct extrapolation correspondingly. However Bayesian forecasting could improve the predictability considerably with priors. The incorporation of non-linear pharmacokinetics in modelling might be a promising approach to improving model predictability.

Citing Articles

Review and External Evaluation of Population Pharmacokinetic Models for Vedolizumab in Patients with Inflammatory Bowel Disease: Assessing Predictive Performance and Clinical Applicability.

Jovanovic M, Homsek A, Markovic S, Kralj D, Svorcan P, Knezevic Ivanovski T Biomedicines. 2025; 13(1.

PMID: 39857627 PMC: 11762475. DOI: 10.3390/biomedicines13010043.


External evaluation of intravenous vancomycin population pharmacokinetic models in adults receiving high-flux intermittent haemodialysis.

Ji C, Garcia J, Sabuga A, Ricard M, Dion F, Rosu V Br J Clin Pharmacol. 2024; 91(3):856-865.

PMID: 39520248 PMC: 11862783. DOI: 10.1111/bcp.16334.


Guiding the starting dose of the once-daily formulation of tacrolimus in " adult renal transplant patients: a population approach.

Fernandez-Alarcon B, Nolberger O, Vidal-Alabro A, Rigo-Bonnin R, Grinyo J, Melilli E Front Pharmacol. 2024; 15:1456565.

PMID: 39364055 PMC: 11447946. DOI: 10.3389/fphar.2024.1456565.


Evaluation of the predictive performance of an online voriconazole dose calculator in children.

Alsultan A, Almofada R, Alomair S, Egelund E, Albassam A, Ali M Eur J Clin Pharmacol. 2024; 80(12):1989-1993.

PMID: 39327261 DOI: 10.1007/s00228-024-03762-x.


External validation of population pharmacokinetic models of tacrolimus in Thai adult liver transplant recipients.

Komenkul V, Sukarnjanaset W, Komolmit P, Wattanavijitkul T Eur J Clin Pharmacol. 2024; 80(8):1229-1240.

PMID: 38695888 DOI: 10.1007/s00228-024-03692-8.


References
1.
Mould D, Upton R . Basic concepts in population modeling, simulation, and model-based drug development-part 2: introduction to pharmacokinetic modeling methods. CPT Pharmacometrics Syst Pharmacol. 2013; 2:e38. PMC: 3636497. DOI: 10.1038/psp.2013.14. View

2.
Merle Y, Aouimer A, Tod M . Impact of model misspecification at design (and/or) estimation step in population pharmacokinetic studies. J Biopharm Stat. 2004; 14(1):213-27. DOI: 10.1081/BIP-120028516. View

3.
Passey C, Birnbaum A, Brundage R, Oetting W, Israni A, Jacobson P . Dosing equation for tacrolimus using genetic variants and clinical factors. Br J Clin Pharmacol. 2011; 72(6):948-57. PMC: 3244642. DOI: 10.1111/j.1365-2125.2011.04039.x. View

4.
Bergstrand M, Hooker A, Wallin J, Karlsson M . Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 2011; 13(2):143-51. PMC: 3085712. DOI: 10.1208/s12248-011-9255-z. View

5.
Andreu F, Colom H, Grinyo J, Torras J, Cruzado J, Lloberas N . Development of a population PK model of tacrolimus for adaptive dosage control in stable kidney transplant patients. Ther Drug Monit. 2014; 37(2):246-55. DOI: 10.1097/FTD.0000000000000134. View